Concepedia

Norman Heyden

NH

Statistics

Publications

8

Citations

847

H-Index

8

Active since

2000

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Stellenbosch University

Bone Health and Osteoporosis Foundation

Helen Hayes Hospital

Norman Heyden is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, bone metabolism, and bone health.

Publications per year

2000–2019

8

Publications

8

Alendronate for the Treatment of Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study

Leanne M. Ward, Frank Rauch, Michael P. Whyte et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 220 citations

, , +16

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 169 citations

, , +10

Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density<sup>1</sup>

Henry G. Bone, Susan L. Greenspan, Clark McKeever et al. · The Journal of Clinical Endocrinology & Metabolism · 2000 · 149 citations · Full text

, , +17

Detection Bias Due to the Effect of Finasteride on Prostate Volume: A Modeling Approach for Analysis of the Prostate Cancer Prevention Trial

Y. C. Cohen, K. S. Liu, Norman Heyden et al. · JNCI Journal of the National Cancer Institute · 2007 · 126 citations · Full text

, , +15

MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study

Abraham Adunsky, Julie Chandler, Norman Heyden et al. · Archives of Gerontology and Geriatrics · 2010 · 65 citations

, , +5

1–5 of 8